BI strikes billion-dollar cancer immunotherapy deal with OSE – pharmaphorum
pharmaphorum |
BI strikes billion-dollar cancer immunotherapy deal with OSE
pharmaphorum Boehringer Ingelheim (BI) has struck a potential billion-dollar deal with OSE Immunotherapeutics to develop a new checkpoint inhibitor cancer immunotherapy, offering the possibility of powerful combination therapies. The deal centres around OSE-172, an … Boehringer builds in immuno-oncology with €1.1bn-plus OSE deal Boehringer Ingelheim, OSE Ink $1.4 Billion Deal Boehringer Ingelheim and OSE Immunotherapeutics Announce Global Immuno-Oncology Partnership to Develop a … |
